Scarica l'app Stockscreener
2.98
0.33%
-0.01
Dopo l'orario di chiusura:
2.99
0.01
+0.34%
Precedente Chiudi:
$2.99
Aprire:
$3.05
Volume 24 ore:
2.11M
Relative Volume:
0.65
Capitalizzazione di mercato:
$540.50M
Reddito:
$4.03M
Utile/perdita netta:
$-198.37M
Rapporto P/E:
-2.3745
EPS:
-1.255
Flusso di cassa netto:
$-158.74M
1 W Prestazione:
+2.76%
1M Prestazione:
-18.80%
6M Prestazione:
-10.24%
1 anno Prestazione:
-55.32%
Intervallo 1D:
$2.92
$3.075
Intervallo di 1 settimana:
$2.77
$3.19
Portata 52W:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.98 | 525.99M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Iniziato | Oppenheimer | Outperform |
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1%Still a Buy? - MarketBeat
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency - AllSci
Citizens reiterates Prime Medicine stock rating on gene editing capabilities By Investing.com - Investing.com Canada
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade
Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade
Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Gets FDA Green Light for Gene Editing Study - Benzinga
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says - marketscreener.com
Prime Medicine (NASDAQ:PRME) Shares Gap UpWhat's Next? - MarketBeat
FDA Clears Prime Medicine to Start Gene Editing Trial After Beam Dispute - GenomeWeb
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine’s PM-647 gains IND approval for AATD - BioWorld News
Prime Medicine (NASDAQ:PRME) Earns Buy Rating from Chardan Capital - MarketBeat
Prime Medicine stock holds at outperform on FDA IND clearance By Investing.com - Investing.com Australia
Prime Medicine stock holds at outperform on FDA IND clearance - Investing.com
Prime Medicine stock jumps 8% after FDA clears PM647 trial - TradingView
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating - Moomoo
Prime Medicine keeps Buy rating with key clinical milestones and potential 2027 BLA for CGD. - Pluang
Chardan Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Stocks to Watch: Akamai, Scholastic, Prime Medicine - Moomoo
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency - TradingView
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Prime Medicine stock surges on FDA IND clearance By Investing.com - Investing.com Australia
Prime Medicine stock surges on FDA IND clearance - Yahoo Finance
Prime Medicine receives FDA clearance for AATD gene therapy - Investing.com
Prime Medicine receives FDA clearance for AATD gene therapy By Investing.com - Investing.com South Africa
FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan
Prime Medicine (PRME) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.5%Should You Sell? - MarketBeat
Can Prime Medicine (NASDAQ:PRME) Afford To Invest In Growth? - Moomoo
Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - Kalkine Media
Prime Medicine (NASDAQ:PRME) Shares Up 11.8%Should You Buy? - MarketBeat
PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum - TradingView
Prime Medicine at H.C. Wainwright conference: platform gains focus By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3%Here's What Happened - MarketBeat
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):